Author | Doris Germain, PhD | OncLive

Author | Doris Germain, PhD

Articles

Dr. Germain on Scientific Rationale Behind Bortezomib/Fulvestrant for HR+ Breast Cancer

February 03, 2015

Video

Doris Germain, PhD, ‎associate professor at Mount Sinai Cancer Institute, discusses the scientific rationale behind a clinical trial comparing fulvestrant alone with bortezomib plus fulvestrant for the treatment of hormone receptor-positive metastatic breast cancer.

x